The phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer who have a homologous recombination repair gene mutation and have progressed on prior treatment with new hormonal agent treatments (e.g. enzalutamide and abiraterone) has demonstrated improvement in overall survival.
GARNET study demonstrates potential of dostarlimab to treat recurrent or advanced endometrial cancer
The GARNET trial demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1) monoclonal antibody, provided clinically meaningful results in women with recurrent or advanced mismatch repair-deficient endometrial cancer who progressed on or after a platinum-based regimen.
Researchers at the MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1).
A new study finds disruptions in health insurance coverage are common in the United States and are associated with poorer cancer care and survival. The study was published in The Journal of the National Cancer institute.
A study from UT Southwestern researchers shows that artificial intelligence can identify a specific genetic mutation in a glioma tumor simply by examining 3D images of the brain—with more than 97% accuracy.
Researchers have demonstrated a novel approach in mouse models that delivers appropriately-targeted chimeric antigen receptor CAR T-cell therapy directly into the cerebrospinal fluid that surrounds the tumor in an effort to treat medulloblastoma and ependymoma.
FDA has approved a supplemental New Drug Application for Zejula (niraparib) an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status.
FDA has granted an accelerated approval to a new dosing regimen of 400 mg every six weeks for Keytruda (pembrolizumab) across all currently approved adult indications, in addition to the current 200 mg every three weeks dosing regimen.
FDA has granted Breakthrough Therapy Designation to mobocertinib (TAK-788) for the treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.
Breast surgeon Kristin L. Brill has joined the Sidney Kimmel Cancer Center–Jefferson Health as enterprise director of Breast Oncology.
